(NYSE: $AGN),(OTCQB: $REPCF) (TSXV: $RP), (NASDAQ: $HOLX), (ZLTQ)

Point Roberts, WA, -April 25, 2017 – Investorideas.com, a global news source covering biotech and medical technology, issues a sector close–up on publicly traded companies competing in the rapidly growing medical aesthetic market.

 

Company news from Allergan (NYSE: AGN), RepliCel (OTCQB:REPCF) (TSXV:RP), Hologic (NASDAQ: HOLX) and ZELTIQ Aesthetics, Inc. (NASDAQ:  $ZLTQ)showcases recent developments in the sector.

 

Read this release in full at http://www.investorideas.com/news/2017/biotech/04252Stocks.asp

According to a new research report by MarketsandMarkets, “Medical Aesthetics Market by Product, “The market is expected to reach USD 13.29 Billion by 2021, at CAGR of 10.8% from 2016 to 2021.”

 

 “A number of factors such as increasing inclination towards minimally invasive and non-invasive aesthetic procedures, rising demand for aesthetic treatments among the male population, and rapid growth in number of cosmetic procedures are driving the growth of the global medical aesthetics market. “

 

The report also notes, “In 2016, North America is expected to hold the largest share of the global medical aesthetic market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR from 2016 to 2021.”

 

Source - http://www.marketwatch.com/story/medical-aesthetics-market-worth-1329-billion-usd-by-2021-2016-11-25-7203319

 

This week, RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions,  announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) covering significant components of the company’s novel, multi-needle dermal injection device. 

 

In the development of propriety cell therapy products targeting pattern baldness (androgenetic alopecia) and aging or sun-damaged skin, RepliCel’s dermatology team identified a need for next-generation dermal injection techologies capable of bringing new levels of precision and control to any substances injected into the skin. 

 

The patent issued by the U.S. Patent and Trademark Office (USPTO) relates to technologies designed to  enable both unparalleled control and repeatable consistency of needle action and product deposition. The patent also relates to the element designed to numb the skin prior to injection with the intended effect of reducing, if not eliminating, the need for local anesthetic prior to aesthetic injection procedures.

 

 

 

The first device being developed under this patent, RCI-02, is designed for injecting soft tissue fillers such as hyaluronic acid (“HA”). According to recent statistics released by the American Society for Plastic Surgery(April 2017), there were over 11 million minimally invasive cosmetic procedures performed nationally in 2016: over 80% were wrinkle treatments (botulinum toxin type-A, such as Botox®, Dysport®) and hyaluronic acid filler injections, totalling an expenditure of over $3 billion. RCI-02 represents the nearest-term commercial opportunity for the Company, which it intends to have market-ready and in the hands of a co-development licensee and commercial partner next year (2018). 

 

 

 

Full news: http://www.investorideas.com/news/2017/biotech/04251REPCF.asp

 

 

 

In late March, Allergan plc, (NYSE: AGN), a leading global pharmaceutical company announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURE™ XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59%) of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months.* Patient satisfaction in the pivotal study was also high: 82% of patients said they were very satisfied at 6 months and 68% at 18 months.

 

 

 

"The FDA approval of JUVÉDERM VOLLURE™ XC demonstrates Allergan's imperative to develop next-generation HA fillers designed to meet different patient needs," said David Nicholson, Chief Research and Development Officer at Allergan. "This commitment to ongoing scientific research and development is one of the factors that make JUVÉDERM®, the number one selling collection of dermal filler products."

 

 

 

Full news: http://www.prnewswire.com/news-releases/juvederm-vollure-xc-approved-by-us-fda-for-correction-of-facial-wrinkles-and-folds-in-adults-over-the-age-of-21-300425947.html

 

 

 

On March 22nd Hologic, Inc. (NASDAQ: HOLX) announced it had completed the acquisition of Cynosure, Inc., a leader in medical aesthetics systems and technologies, for $66 per share in cash.

 

 

 

"We are pleased to complete our acquisition of Cynosure, and look forward to working with Michael Davin and the entire Cynosure team to achieve even greater success in the large, rapidly growing medical aesthetics market," said Steve MacMillan, Hologic's Chairman, President and Chief Executive Officer. "Acquiring Cynosure, combined with divesting our blood screening business, fundamentally reshapes our business portfolio and makes us a stronger, faster-growing company."

 

 

 

Full news: https://finance.yahoo.com/news/hologic-acquire-cynosure-leader-medical-130000368.html

 

 

 

On April 6th Allergan plc (NYSE: AGN),  and ZELTIQ® Aesthetics, Inc. ( NASDAQ:  $ZLTQ),  a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has expired with respect to Allergan's proposed acquisition of ZELTIQ.

 

On February 13, 2017, Allergan and ZELTIQ entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ. Following the announcement of the transaction, each of Allergan and ZELTIQ filed a Notification and Report Form pursuant to the HSR Act with the Antitrust Division of the U.S. Department of Justice and the Federal Trade Commission.

 

 

 

Full news : https://finance.yahoo.com/news/allergan-zeltiq-announce-expiration-hart-120000861.html

 

 

 

About Investorideas.com - News that Inspires Big Ideas

 

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

 

Sectors we cover in include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security including biometrics, Latin America, sports, entertainment, luxury brands and gaming.

 

 

 

The Investorideas.com content portfolio goes beyond the www.investorideas.comsite to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

 

 

 

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

 

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

 

 

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure – the following is a paid news release for RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP). Learn more about our newswire. pricing and how to publish your news-http://www.investorideas.com/News-Upload/

 

 

 

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

 

 

 

Contact Investorideas.com

 

 

 

800-665-0411

 

 

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

 

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks